Starpharma Investor Presentation for Citi Conference
Filed with ASX · · 35 pages · English
Melbourne, Australia; 17 October 2018: Starpharma (ASX: SPL, OTCQX: SPHRY) will today participate in Citi's 10th Annual Australian and New Zealand Investment Conference in Sydney. The invitation-only Citi Conference brings together 65 ASX listed companies with over 700 investors and fund managers. During the event Starpharma’s Chief Executive Officer, Dr Jackie Fairley, will be presenting the atta
Starpharma Holdings Limited on 6ix
In the deck
Earlier from Starpharma
- DEP irinotecan outperforms in pancreatic cancer model
- AstraZeneca DEP Bcl2/xL inhibitors show compelling efficacy
- Annual report and full year financial results
- VivaGel BV NDA advances to next stage of FDA review
- Starpharma licenses VivaGel BV to Mundipharma for Europe
Later from Starpharma
- DEP products outperform in human pancreatic cancer model
- US VivaGel BV licensed for A$142M milestones plus royalties
- US FDA requests further data for VivaGel BV approval
- VivaGel condom receives final regulatory approval in Japan
- Response to ASX Aware Letter
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma